<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="33da7a2b-b35d-fe3e-e063-6394a90ad2db"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use NEURACEQ safely and effectively. See full prescribing information for NEURACEQ.
 <br/>
NEURACEQ (florbetaben F 18 injection), for intravenous use
 <br/>
Initial U.S. Approval: 2014
</title>
   <effectiveTime value="20250428"/>
   <setId root="b0915068-cfd4-4d72-b9f8-7e31fe83cd1e"/>
   <versionNumber value="39"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="735628575"/>
            <name>Life Molecular Imaging, Ltd</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="829109441"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079854636"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="928455851"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="025600556"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="032324142"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="832599976"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="006320902"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="078623800"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118258354"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="008017970"/>
                        <name>SOFIE Co. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079932634"/>
                        <name>N-Molecular, Inc. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079932640"/>
                        <name>N-Molecular, Inc. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="079932600"/>
                        <name>N-Molecular, Inc. dba SOFIE</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="080871737"/>
                        <name>Jubilant DraxImage Inc. dba Jubilant Radiopharma</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="080871701"/>
                        <name>Jubilant DraxImage Inc. dba Jubilant Radiopharma</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="117608150"/>
                        <name>PharmaLogic Colorado, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="118408248"/>
                        <name>PharmaLogic Cincinnati, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="119319723"/>
                        <name>PharmaLogic Salt Lake City, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C91403" displayName="positron emission tomography drug production" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="33db3340-1df0-5a4c-e063-6394a90a5ad4"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250428"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54828-001" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Neuraceq</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Florbetaben F 18</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="118"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="4.4"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PQ6CK8PD0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ASCORBIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="28.8"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="S033EH8359" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ASCORBATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="677.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mCi" value="135"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TLA7312TOI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLORBETABEN F-18</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TLA7312TOI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLORBETABEN F-18</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="54828-001-30" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43186" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CONTAINER"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20140320"/>
                                          <high value="20220610"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="54828-001-50" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43186" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CONTAINER"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220613"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA204677" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140320"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="L40510081-aa80-4b75-9b8e-64d00efb1361">
               <id root="33d8ccfc-3294-6154-e063-6294a90a5187"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.</paragraph>
                  <paragraph>
                     <br/>  A negative Neuraceq scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.
 </paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="underline">Limitations of Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>
                     <br/>  • A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. 
  <br/>  • Safety and effectiveness of Neuraceq have not been established for: 
  <br/>     o Predicting development of dementia or other neurologic conditions; 
  <br/>     o Monitoring responses to therapies.

 </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>• A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder.</paragraph>
                        <paragraph>• Safety and effectiveness of Neuraceq have not been established for:    </paragraph>
                        <paragraph>   • Predicting development of dementia or other neurologic conditions </paragraph>
                        <paragraph>   • Monitoring responses to therapies</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L71f3f8d8-b0f2-4203-8fd3-307d0a2b8f81">
               <id root="33d8ccfc-3295-6154-e063-6294a90a5187"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Use appropriate radiation handling measures (
 
    <linkHtml href="#Le8a82772-df66-4325-b168-0ecebb7b21d2">2.1</linkHtml>).

   </paragraph>
                        <paragraph>•      The recommended dose is 300 MBq (8.1 mCi) as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL. (
 
    <linkHtml href="#L0720401b-783c-422c-8003-8b7ca70f4968">2.2</linkHtml>)

   </paragraph>
                        <paragraph>•      Obtain 15 minute to 20 minute PET images starting from 45 minutes to 130 minutes after intravenous administration (
 
    <linkHtml href="#Lfcbde442-54f0-4320-90a1-6b4b74b3b747">2.3</linkHtml>)

   </paragraph>
                        <paragraph>•      Image interpretation: refer to full prescribing information (
 
    <linkHtml href="#La23c312e-cf34-4dd5-a87a-34e0c1d191ac">2.4</linkHtml>)

   </paragraph>
                        <paragraph>•      The radiation absorbed dose from a 300 MBq (8.1 mCi) dose of Neuraceq is 5.8 mSv in an adult (
 
    <linkHtml href="#L084be218-5b19-4e13-9826-1fd3f213027e">2.5</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Le8a822-df66-4325-b168-0ecebb7b21d2">
                     <id root="33d8ccfc-3296-6154-e063-6294a90a5187"/>
                     <code code="50741-8" codeSystem="2.16.840.1.113883.6.1" displayName="SAFE HANDLING WARNING SECTION"/>
                     <title>2.1 Radiation Safety - Drug Handling</title>
                     <text>
                        <paragraph>Neuraceq is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure during administration [
 
  <content styleCode="italics">see Warnings and Precautions (5.2)</content>]. Use waterproof gloves and effective shielding, including lead-glass syringe shields when handling and administering Neuraceq. Radiopharmaceuticals, including Neuraceq, should only be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radioactive materials, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.

 </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="L0720401b-783c-422c-8003-8b7ca70f4968">
                     <id root="33d8ccfc-3297-6154-e063-6294a90a5187"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.2 Recommended Dosing and Administration Instructions</title>
                     <text>
                        <paragraph>The recommended dose of Neuraceq is 300 MBq (8.1 mCi), maximum 30 mcg mass dose, administered as a single slow intravenous bolus (6 sec/mL) in a total volume of up to 10 mL.  The dose may vary depending on the patient’s body weight, and image acquisition parameters [
 
  <content styleCode="italics">see Clinical Studies (14)</content>].

 </paragraph>
                        <paragraph>­-  Inspect the radiopharmaceutical dose solution prior to administration and do not use it if it contains particulate matter</paragraph>
                        <paragraph>-  Use aseptic technique and radiation shielding to withdraw and administer Neuraceq solution.</paragraph>
                        <paragraph>­-  Measure the activity of Neuraceq with a dose calibrator immediately prior to injection.</paragraph>
                        <paragraph>-  Do not dilute Neuraceq</paragraph>
                        <paragraph>-  The injection must be intravenous in order to avoid irradiation as a result of local extravasation, as well as imaging artifacts. Verify patency of the indwelling catheter by a saline test injection prior to administration of Neuraceq.</paragraph>
                        <paragraph>-  An injection (6 sec/mL) into a large vein in the arm is recommended, followed by a saline flush of approximately 10 mL.</paragraph>
                        <paragraph>­-  Dispose of unused product in a safe manner in compliance with applicable regulations</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Lfcbde442-54f0-4320-90a1-6b4b74b3b747">
                     <id root="33d8ccfc-3298-6154-e063-6294a90a5187"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.3 Image Acquisition Guideline</title>
                     <text>
                        <paragraph>Acquire PET images over 15 minutes to 20 minutes starting 45 minutes to 130 minutes after Neuraceq injection. Keep the patient supine with the head positioned to center the brain, including the cerebellum, in the PET scanner field of view. Reduce head movement with tape or other flexible head restraints if necessary. Reconstruction should include attenuation correction with resulting transaxial pixel sizes between 2 mm and 3 mm.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="La23c312e-cf34-4dd5-a87a-34e0c1d191ac">
                     <id root="33d90abd-2ec6-8366-e063-6294a90a515b"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.4 Image Display and Interpretation</title>
                     <text>
                        <paragraph>Neuraceq images should be interpreted only by readers who successfully complete Electronic Media- or In-Person Training provided by the manufacturer [see Warnings and Precautions (5.1)]. The objective of Neuraceq image interpretation is to estimate β-amyloid neuritic plaque density in brain gray matter, not to make a clinical diagnosis. Image interpretation is performed independently of a patient’s clinical features and relies upon the recognition of image features in certain brain regions.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Image Display</content>
                           <br/>
PET images should be displayed in the transaxial orientation using gray scale or inverse gray scale. The sagittal and coronal planes may be used for additional orientation purposes. CT or MR images may be helpful for anatomic reference purposes. However, visual assessment should be performed using the axial planes according to the recommended reading methodology.
 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Image Interpretation</content>
                           <br/>
Interpretation of the images is made by visually comparing the activity in cortical gray matter with activity in adjacent white matter. Regions displayed in the PET images which ‘anatomically’ correspond to white matter structures (e.g., the cerebellar white matter or the splenium) should be identified to help the readers orient themselves. Images should be viewed and assessed in a systematic manner, starting with the cerebellum and scrolling up through the lateral temporal and frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes. For a gray matter cortical region to be assessed as showing ‘tracer uptake’, the majority of slices from the respective region must be affected.
 </paragraph>
                        <paragraph>For each patient, the PET image assessment is categorized as either “β-amyloid-positive” or “β-amyloid-negative”. This determination is based on the assessment of tracer uptake in the gray matter of the following four brain regions: the temporal lobes, the frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes; according to the following ‘rules for assessment’ [see Warnings and Precautions (5.1.)]:</paragraph>
                        <paragraph>• 
  <content styleCode="bold">β-amyloid negative</content>- tracer uptake (i.e., signal intensity) in gray matter is lower than in white matter in all four brain regions (no β-amyloid deposition)
 </paragraph>
                        <paragraph>
                           <br/>
• 
  <content styleCode="bold">β-amyloid positive</content>- smaller area(s) of tracer uptake equal to or higher than that present in white matter extending beyond the white matter rim to the outer cortical margin involving the majority of the slices within at least one of the four brain regions (“moderate” β-amyloid deposition), or a large confluent area of tracer uptake equal to or higher than that present in white matter extending beyond the white matter rim to the outer cortical margin and involving the entire region including the majority of slices within at least one of the four brain regions (“pronounced” β-amyloid deposition). There is no known clinical or histopathologic correlation distinguishing “moderate” from “pronounced” β-amyloid deposition.
 </paragraph>
                        <paragraph>
                           <br/>
Examples of positive and negative scans for each of the four brain regions are illustrated in Figure 1.
 </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="img_33d90c65-a18e-9cf7-e063-6294a90abd4b"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1 Axial view of negative (top row) and positive (bottom row) Neuraceq PET scans</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">Cerebellum</content>: 
  <content styleCode="italics">A contrast between the white matter (arrows) and gray matter is seen in both negative and positive scans. Extracerebral tracer uptake in scalp and in the posterior sagittal sinus (arrowhead) can be seen. Lateral temporal lobes: Spiculated or “mountainous” appearance of the white matter (arrows) is seen in the negative scan, and radioactive signal does not reach the outer rim of the brain (dashed line) due to lower tracer uptake in the gray matter. The positive scan shows a “plumped”, smooth appearance of the outer border of the brain parenchyma (dashed line) due to tracer uptake in the gray matter. Frontal Lobes: Spiculated appearance of the white matter in the frontal lobes (arrows) is seen in the negative scan. The positive scan shows the tracer uptake in these regions has a “plumped”, smooth appearance due to the increased gray matter signal (dashed line). Posterior cingulate/precuneus: Adjacent and posterior to the splenium (arrow), these regions appear as a hypo-intense “hole” (circle) in the negative scan, whereas this hole is “filled-up” (circle) in the positive scan. Parietal lobes: In the negative scan, the midline between the parietal lobes can be easily identified (long arrow); white matter has a spiculated appearance (short arrow) with low signal near the outer rim of the brain (dashed line). In the positive scan, the midline between the parietal lobes is much thinner. The cortical areas are “filled-up” and are smooth in appearance as tracer uptake extends to the outer rim of the brain.</content>
                        </paragraph>
                        <paragraph>Some scans may be difficult to interpret due to image noise, atrophy with a thinned cortex, or image blur. If a co-registered computerized tomography (CT) image is available, the CT image may be used to clarify the relationship of the Neuraceq uptake and the gray matter anatomy.</paragraph>
                        <paragraph/>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <observationMedia ID="img_33d90c65-a18e-9cf7-e063-6294a90abd4b">
                           <text>Figure1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="Figure.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="L084be218-5b19-4e13-9826-1fd3f213027e">
                     <id root="33d8ccfc-329a-6154-e063-6294a90a5187"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.5 Radiation Dosimetry</title>
                     <text>
                        <paragraph>The estimated radiation absorbed doses for adults from intravenous injection of Neuraceq are shown in Table 1.</paragraph>
                        <table ID="t1" border="1">
                           <caption>Table 1 Estimated Radiation Absorbed Doses from Intravenous Injection of Neuraceq</caption>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Organ/Tissue</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Mean Absorbed Radiation Dose per Unit Administered Activity</content>
                                    <br/>
                                    <content styleCode="bold">[mcGy/MBq]</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Adrenals</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Brain</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">13</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Breasts</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">7</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Gallbladder Wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">137</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Heart Wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">14</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Kidneys</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">24</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Liver</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">39</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Lower Large Intestine-Wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">35</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Lungs</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">15</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Muscle</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">10</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Osteogenic Cells</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">15</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Ovaries</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">16</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Pancreas</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">14</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Red Marrow</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">12</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Skin</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">7</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Small Intestine</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">31</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Spleen</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">10</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Stomach Wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">12</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Testes</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">9</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Thymus</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">9</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Thyroid</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">8</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Upper Large Intestine-Wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">38</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Urinary Bladder Wall</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">70</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Uterus</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">16</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Total Body</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">11</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Effective Dose (mcSv/MBq)</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">19</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The effective dose resulting from a 300 MBq (8.1 mCi) administration of Neuraceq in adult subjects is 5.8 mSv. The use of a CT scan to calculate attenuation correction for reconstruction of Neuraceq images (as done in PET/CT imaging) will add radiation exposure. Diagnostic head CT scans using helical scanners administer an average of 2.2 mSv ± 1.3 mSv effective dose (CRCPD Publication E-07-2, 2007). The actual radiation dose is operator and scanner dependent. Thus, the total combined radiation exposure from Neuraceq administration and subsequent scan on a PET/CT scanner is estimated to be 8 mSv. </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="La8846ab3-2867-45ad-8059-b8680cb45a85">
               <id root="33d8ccfc-329b-6154-e063-6294a90a5187"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Neuraceq is available in 50 mL multi-dose vials containing a clear solution at a strength of 50 MBq/mL to 5,000 MBq/mL (1.4 mCi/mL to 135 mCi/mL) florbetaben F18 at end of synthesis. At time of administration 300 MBq (8.1 mCi) are contained in up to 10 mL of solution for injection.</paragraph>
               </text>
               <effectiveTime value="20220614"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>50 mL multi-dose vials containing a clear injectable solution at a strength of 50 MBq/mL to 5,000 MBq/mL (1.4 mCi/mL to 135 mCi/mL) florbetaben F18 at end of synthesis (EOS). At time of administration 300 MBq (8.1 mCi) are contained in up to 10 mL solution for injection.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L88e020c6-59b8-4712-b15a-4fe7a31d1b94">
               <id root="33d8ccfc-329c-6154-e063-6294a90a5187"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20140321"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Lc56ab639-adb7-4022-8987-c1724a5a8f95">
               <id root="33d8ccfc-329d-6154-e063-6294a90a5187"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20140324"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•     Image interpretation errors (especially false positives) have been observed (
 
    <linkHtml href="#L21122933-77af-4150-ac53-3a9d804ed5a6">5.1</linkHtml>).

   </paragraph>
                        <paragraph>•     Neuraceq, like all radiopharmaceuticals, contributes to a patient’s long-term cumulative radiation exposure. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure (
 
    <linkHtml href="#Lc7af6f52-a800-4599-be7d-1e10852340d1">5.2</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L21122933-77af-4150-ac53-3a9d804ed5a6">
                     <id root="33d8ccfc-329e-6154-e063-6294a90a5187"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk for Image Misinterpretation and Other Errors</title>
                     <text>
                        <paragraph>Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [
 
  <content styleCode="italics">see Clinical Studies (14)</content>]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.

 </paragraph>
                     </text>
                     <effectiveTime value="20140324"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc7af6f52-a800-4599-be7d-1e10852340d1">
                     <id root="33d8ccfc-329f-6154-e063-6294a90a5187"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Radiation Risk</title>
                     <text>
                        <paragraph>Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure.  Long-term cumulative radiation exposure is associated with an increased risk of cancer.  Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [
 
  <content styleCode="italics">see Dosage and Administration (2.1)</content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20140324"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L2c566860-7d97-436f-946f-ccb4d47f2935">
               <id root="33d8ccfc-32a0-6154-e063-6294a90a5187"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20250428"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.1 %), and pain (3.4%).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Life Molecular Imaging at 1-833-491-2524 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="underline">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L23af417e-b140-41b1-904e-9475ddee8456">
                     <id root="33d8ccfc-32a1-6154-e063-6294a90a5187"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rate observed in clinical practice.</paragraph>
                        <paragraph>The overall safety profile of Neuraceq is based on data from 1,090 administrations of Neuraceq to 872 subjects. No serious adverse reactions related to Neuraceq administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain. All adverse reactions were mild to moderate in severity and of short duration. The most commonly reported adverse reactions (occurring in at least 1% of subjects) during Neuraceq clinical trials are shown in Table 2. </paragraph>
                        <table ID="t2" width="594" border="1">
                           <caption>Table 2 Adverse Reactions with a Frequency ≥1% Reported in Clinical Trials (n = 1,090 Administrations in 872 Subjects)</caption>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Adverse drug reaction</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">n (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Injection / application site erythema</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">18 (1.7)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Injection site irritation</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">12 (1.1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Injection site pain</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">37 (3.4)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250428"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L7beef04b-d25c-4c65-9cbe-1fef74c5b892">
               <id root="33d8ccfc-32a2-6154-e063-6294a90a5187"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.</paragraph>
               </text>
               <effectiveTime value="20240501"/>
            </section>
         </component>
         <component>
            <section ID="Lcc42cf5a-d25d-4702-a6ee-c8d4e4178ca7">
               <id root="33d8ccfc-32a3-6154-e063-6294a90a5187"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20220614"/>
               <component>
                  <section ID="L83c6fe37-e6b2-405a-a7a8-ae39831147a9">
                     <id root="33d8ccfc-32a4-6154-e063-6294a90a5187"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on Neuraceq use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  Animal reproduction studies have not been conducted with Neuraceq. All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20220614"/>
                  </section>
               </component>
               <component>
                  <section ID="L2b8cf05f-1d63-441d-8bd4-6d400c102a83">
                     <id root="33d8ccfc-32a5-6154-e063-6294a90a5187"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding [
 
  <content styleCode="italics">see Clinical Considerations</content>]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.

 </paragraph>
                        <paragraph>
                           <br/>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard breast milk for 24 hours after administration of Neuraceq.</paragraph>
                     </text>
                     <effectiveTime value="20200115"/>
                     <excerpt>
                        <highlight>
                           <text>
                              <paragraph>Lactation:  A lactating woman may pump and discard breast milk for 24 hours after Neuraceq administration.</paragraph>
                           </text>
                        </highlight>
                     </excerpt>
                  </section>
               </component>
               <component>
                  <section ID="L28356ec6-a36f-4bdb-b66a-2dfa99408f72">
                     <id root="33d8ccfc-32a6-6154-e063-6294a90a5187"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Neuraceq is not indicated for use in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20140321"/>
                  </section>
               </component>
               <component>
                  <section ID="L33971b56-76cd-4ff8-8289-655cedfe20a3">
                     <id root="33d8ccfc-32a7-6154-e063-6294a90a5187"/>
                     <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 872 subjects in clinical studies of Neuraceq, 603 (69%) were 65 years or over, while 304 (35%) were 75 years or over. No overall differences in safety were observed between these subjects and younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20140321"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L6dbb5386-7079-4e56-b522-cd92fcaae79b">
               <id root="33d8ccfc-32a8-6154-e063-6294a90a5187"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes.</paragraph>
                  <paragraph>In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition.</paragraph>
               </text>
               <effectiveTime value="20240501"/>
            </section>
         </component>
         <component>
            <section ID="L16ac5b00-ddeb-4056-ad64-a8d947e215df">
               <id root="33d9fbcf-df56-47ed-e063-6294a90a6377"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Neuraceq contains florbetaben F18, a molecular imaging agent that binds to β-amyloid plaques in the brain, and is intended for use with PET imaging. Chemically, florbetaben F18 is described as 4-[(E)-2-(4-{2-[2-(2-[18F] fluoroethoxy) ethoxy] ethoxy}phenyl)vinyl]-N-methylaniline. The molecular weight is 358.45 and the structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_33d9fbcf-df55-47ed-e063-6294a90a6377"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Neuraceq is a sterile, non-pyrogenic radioactive diagnostic agent for intravenous injection. The clear solution is supplied ready to use. Each mL contains up to 3 micrograms and 50 MBq to 5,000 MBq (1.4 mCi to 135 mCi) florbetaben F18 end of synthesis, 4.4 mg ascorbic acid, 118 mg ethanol, 200 mg macrogol 400, 28.8 mg sodium ascorbate. The pH of the solution is between 4.5 and 7.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="img_33d9fbcf-df55-47ed-e063-6294a90a6377">
                     <text>Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="L7523a103-d098-496c-b2ae-4d0c957cf01f">
                     <id root="33d8ccfc-32aa-6154-e063-6294a90a5187"/>
                     <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
                     <title>11.1 Physical Characteristics</title>
                     <text>
                        <paragraph>Neuraceq is radiolabeled with [
 
  <sup>﻿18</sup>F] fluorine (F18) that decays by positron (ß
 
  <sup>﻿+</sup>) emission to O 18 and has a half-life of 109.8 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons resulting from the interaction of the emitted positron with an electron (Table 3).

 </paragraph>
                        <table ID="t3" width="668" border="1">
                           <caption>Table 3: Principal Radiation Produced from Decay of Fluorine 18</caption>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Radiation</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Energy Level (keV)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Abundance (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Positron</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">249.8</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">96.7</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Gamma</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">511</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">193.4</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="L75953ea0-4a2a-40db-892f-3945360b02bc">
                     <id root="33d8ccfc-32ab-6154-e063-6294a90a5187"/>
                     <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
                     <title>11.2 External Radiation</title>
                     <text>
                        <paragraph>The point source air-kerma coefficient
 
  <sup>a</sup> for F18 is 3.74E -17 Gy m
 
  <sup>﻿2</sup>/ (Bq s); this coefficient was formerly defined as the specific gamma-ray constant of 5.7 R/hr/mCi at 1 cm. The first half-value thickness of lead for F18-fluorine gamma rays is approximately 6 mm
 
  <sup>b</sup>. The relative reduction of radiation emitted by F18-fluorine that results from various thicknesses of lead shielding is shown in Table 4. The use of ~8 cm of lead (Pb) will decrease the radiation transmission (i.e. exposure) by a factor of about 10,000.

 </paragraph>
                        <table ID="t4" width="672" border="1">
                           <caption>Table 4: Radiation Attenuation of 511 keV Gamma Rays by Lead Shielding</caption>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Shield Thickness</content>
                                    <br/>
                                    <content styleCode="bold">cm of Lead (Pb)</content>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                                    <content styleCode="bold">Coefficient of Attenuation</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">0.6</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">2</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">4</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.01</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">6</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.001</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule" valign="top">8</td>
                                 <td align="center" styleCode="Botrule Rrule" valign="top">0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>Eckerman KF and A Endo. MIRD: Radionuclide Data and Decay Schemes, 2nd Edition, 2008. 
  <br/>
                           <sup>b</sup>Derived from data in NCRP Report No. 49. 1998, Appendix C

 </paragraph>
                     </text>
                     <effectiveTime value="20140324"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lc9cc9519-89ec-4fd5-bc5d-4b912533ef48">
               <id root="33d8ccfc-32ac-6154-e063-6294a90a5187"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20240501"/>
               <component>
                  <section ID="La7188fed-2ca6-42c5-b407-5680d5fab57a">
                     <id root="33d8ccfc-32ad-6154-e063-6294a90a5187"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Florbetaben F18 is a F18-labeled stilbene derivative, which binds to β-amyloid plaques in the brain.  The F 18 isotope produces a positron signal that is detected by a PET scanner.
 
  <sup>﻿3</sup>H-florbetaben in vitro binding experiments reveal two binding sites (Kd of 16 nM and 135 nM) in frontal cortex homogenates from patients with AD. Binding of florbetaben F18 to β-amyloid plaques in post-mortem brain sections from patients with AD using autoradiography correlates with both immunohistochemical and Bielschowsky silver stains. Florbetaben F 18 does not bind to tau or α-synuclein in tissue from patients with AD. Neither Neuraceq nor non-radioactive florbetaben F 19 bind to AT8 positive tau deposits in brain tissue from patients with frontotemporal dementia (FTD), using autoradiography and immunohistochemistry, respectively.

 </paragraph>
                     </text>
                     <effectiveTime value="20240501"/>
                  </section>
               </component>
               <component>
                  <section ID="Lc7b3a895-a22c-4fd4-9293-ef60dea6c64d">
                     <id root="33d8ccfc-32ae-6154-e063-6294a90a5187"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Following intravenous administration, Neuraceq crosses the blood brain barrier and shows differential retention in brain regions that contain β-amyloid deposits. Differences in signal intensity between brain regions showing specific and non-specific Neuraceq uptake form the basis for the image interpretation method.</paragraph>
                     </text>
                     <effectiveTime value="20140321"/>
                  </section>
               </component>
               <component>
                  <section ID="L973ec755-8eee-4a70-9457-f7b517407af6">
                     <id root="33d8ccfc-32af-6154-e063-6294a90a5187"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Ten minutes after intravenous bolus injection of 300 MBq of Neuraceq in human volunteers, approximately 6% of the injected radioactivity was distributed to the brain. Florbetaben F 18 plasma concentrations declined by approximately 75%  at 20 minutes post-injection, and by approximately  90% at 50 minutes. The F 18 in circulation during the 45 minute to 130 minute imaging window was principally associated with polar metabolites of florbetaben. Florbetaben F 18 was 98.5% bound to plasma proteins and was eliminated from plasma primarily via the hepatobiliary route with a mean biological half-life of approximately 1 hour.
 
  <content styleCode="italics">In vitro</content>studies show that metabolism of florbetaben is predominantly catalyzed by CYP2J2 and CYP4F2. At 12 hours post-administration, approximately 30% of the injected radioactivity had been excreted in urine. Almost all F18 radioactivity in urine was excreted as polar metabolites of florbetaben F18 and only trace amounts of florbetaben F18 were detected.

 </paragraph>
                        <paragraph>In i
 
  <content styleCode="italics">n vitro</content>studies using human liver microsomes, florbetaben did not inhibit cytochrome P450 enzymes at concentrations present
 
  <content styleCode="italics">in vivo</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20220614"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L598a25f2-157f-44fa-9339-ff70ccf5956f">
               <id root="33d8ccfc-32b0-6154-e063-6294a90a5187"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20240501"/>
               <component>
                  <section ID="L7b1af264-6ced-4a5f-968e-cf942dc5fc0d">
                     <id root="33d8ccfc-32b1-6154-e063-6294a90a5187"/>
                     <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Animal studies have not been performed to evaluate the carcinogenic potential of florbetaben.</paragraph>
                        <paragraph>Florbetaben did not demonstrate mutagenic potential in an i
 
  <content styleCode="italics">n vitro</content>bacterial mutation assay (Ames test) using five strains of
 
  <content styleCode="italics">Salmonella typhimurium</content>and one strain of
 
  <content styleCode="italics">Escherichia coli</content>or in an i
 
  <content styleCode="italics">n vitro</content>chromosomal aberration assay using human peripheral lymphocytes in the absence and presence of a metabolic activator.

 </paragraph>
                        <paragraph>No study on impairment of male or female fertility and reproductive performance was conducted in animals.</paragraph>
                     </text>
                     <effectiveTime value="20240501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L074355ed-2ba3-4a3e-b5ca-46c8ac7128b9">
               <id root="33d8ccfc-32b2-6154-e063-6294a90a5187"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Neuraceq (doses ranging from 240 MBq to 360 MBq) was evaluated in three single arm clinical studies (Study A-C) that examined images from adults with a range of cognitive function, including some end-of-life patients who had agreed to participate in a post-mortem brain donation program. Subjects underwent Neuraceq injection and scan, then had images interpreted by independent readers masked to all clinical information.</paragraph>
                  <paragraph>The Standard of Truth (SoT) was based on the histopathologic examination using Bielschowsky silver staining (BSS) of six brain regions assessed by a Pathology Consensus Panel masked to all clinical information (including PET scan results). Neuraceq PET imaging results (negative or positive) corresponded to a histopathology derived plaque score based on the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria using neuritic plaque counts (Table 5). For the subject level SoT, if in any of the six regions β-amyloid neuritic plaques were more than sparse, the subject was classified as positive; if in none of the regions the β-amyloid neuritic plaques were assessed as being more than sparse, the subject was classified as negative.</paragraph>
                  <table ID="t5" width="462" border=".25">
                     <caption>Table 5: ß-Amyloid Neuritic Plaque Counts Correlation to Image Results</caption>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Plaque Counts</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">CERAD Score</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Neuraceq PET Image Result</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">&lt;1</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">None</content>
                           </td>
                           <td rowspan="2" align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Negative</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">1 - 5</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Sparse</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">6 - 19</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Moderate</content>
                           </td>
                           <td rowspan="2" align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Positive</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">≥20</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Frequent</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Study A evaluated Neuraceq PET images from 205 subjects and compared the results to postmortem truth standard assessments of brain β-amyloid neuritic plaque density in subjects who died during the study. The median age was 79 years (range 48 to 98 years) and 52% of the subjects were male. By medical history 137 study participants had AD, 31 had other non-AD dementia, 5 had dementia with Lewy Bodies (DLB), and 32 had no clinical evidence of dementia. Interpretation of images from 82 autopsied subjects was compared to the subject level histopathology SoT. Three readers, after undergoing in-person tutoring, interpreted images using a clinically applicable image interpretation methodology [
 
  <content styleCode="italics">see Dosage and Administration (2.4)</content>]. At autopsy, the subject level brain β-amyloid neuritic plaque density category was: frequent (n = 31); moderate (n = 21); sparse (n = 17); or none (n = 13). Results from Study A are presented in Table 6 and Table 7.

 </paragraph>
                  <paragraph>In Study B five independent, blinded readers underwent the Electronic Media Training in the clinically applicable image interpretation methodology
 
  <content styleCode="italics">[see Dosage and Administration (2.4)</content>] and assessed images from the same 82 end-of-life subjects who enrolled in Study A. The time interval between the Neuraceq scan and death was less than one year for 45 patients, between one and two years for 23 patients and more than two years for 14 patients. Results from Study B can also be found in Table 6 and Table 7.

 </paragraph>
                  <paragraph>Study C evaluated the reliability and reproducibility of the clinically applicable image interpretation methodology
 
  <content styleCode="italics">[see Dosage and Administration</content>(
 
  <content styleCode="italics">2.4)</content>] using the Electronic Media Training; 461 images from previous clinical studies were included from subjects with a range of diagnoses. Five new readers assessed randomly provided images from subjects with a truth standard (54 subjects who underwent an autopsy) and without a truth standard (51 subjects with mild cognitive impairment, 182 subjects with AD, 35 subjects with other dementias, 5 subjects with Parkinson’s Disease and 188 healthy volunteers). Among the 461 subjects, the median age was 72 years (range 22 to 98), 197 were females, and 359 were Caucasian. Image reproducibility data for various subject groups in Study C are presented in Table 8. Inter-reader agreement across all 5 readers had a kappa coefficient of 0.79 (95% CI 0.77, 0.83). The performance characteristics in 54 subjects with SoT were similar to those measured in Studies A and B. Additionally, intra-reader reproducibility was assessed from 46 images (10%); the percentage of intra- reader agreement for the 5 readers ranged from 91% to 98%.

 </paragraph>
                  <table ID="t6" width="832px" border="1">
                     <caption>Table 6: Neuraceq Results by Reader Training Method using BSS as Standard of Truth</caption>
                     <tbody>
                        <tr>
                           <td rowspan="2" colspan="2" align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Read Result</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">In-Person Training (Study A)</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Electronic Media Training (Study B)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">n=82</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">n=82</content>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">Sensitivity (%)</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">Median</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">98</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">96</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">Range among the readers</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">96-98</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">90-100</td>
                        </tr>
                        <tr>
                           <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">Specificity (%)</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">Median</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">80</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">77</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">Range among the readers</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">77-83</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">47-80</td>
                        </tr>
                     </tbody>
                  </table>
                  <table ID="t7" width="834px" border="1">
                     <caption>Table 7: Neuraceq Correct and Erroneous Read Results by Reader Training Method</caption>
                     <tbody>
                        <tr>
                           <td rowspan="3" align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Read Result</content>
                           </td>
                           <td colspan="3" align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">In-Person Training (Study A)</content>
                           </td>
                           <td colspan="5" align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Electronic Media Training (Study B)</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Reader</content>
                           </td>
                           <td colspan="5" align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Reader</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">1</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">2</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">3</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">4</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">5</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">6</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">7</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">8</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">Correct</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">75</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">74</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">75</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">73</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">65</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">71</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">73</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">69</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">False Negative</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">3</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">1</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">5</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">2</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">False Positive</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">5</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">6</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">6</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">16</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">6</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">13</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="italics">BSS was the Histopathology Standard of Truth</content>
                  </paragraph>
                  <table ID="t8" width="837px" border="1">
                     <caption>Table 8: Reproducibility of Scan Results among Readers in Various Subject Groups
  
   <sup>a</sup>
                     </caption>
                     <tbody>
                        <tr>
                           <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Subject Group by Cognitive Status and Standard of Truth (SoT)</content>
                           </td>
                           <td rowspan="2" align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Positive Scans n
     
      <sup>b</sup>
                              </content>
                           </td>
                           <td rowspan="2" align="center" styleCode="Botrule Rrule Toprule" valign="middle">
                              <content styleCode="bold">Kappa (95% CI)</content>
                           </td>
                           <td colspan="3" align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">Percent of Scans with Inter-reader Agreement</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">3 of 5 readers agreed</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">4 of 5 readers agreed</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">
                              <content styleCode="bold">5 of 5 readers agreed</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">All subjects (n=454)</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">212</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.80 
     <br/>  (0.77, 0.83)
    </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">6</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">15</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">78</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">Subjects without SoT (n=394)</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">175</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.80 
     <br/>  (0.77, 0.83)
    </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">6</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">15</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">79</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">Subjects with SoT (n=60)</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">37</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.75 
     <br/>  (0.67, 0.83)
    </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">10</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">15</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">75</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">AD (n=176)</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">139</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.77 
     <br/>  (0.72, 0.81)
    </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">10</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">83</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">HV (n=188)</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">26</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.55 
     <br/>  (0.49, 0.58)
    </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">7</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">15</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">77</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">MCI (n=50, all without SoT)</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">28</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.84 
     <br/>  (0.75, 0.92)
    </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">20</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">80</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="middle">Other Dementias (n=40)</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">18</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">0.65 
     <br/>  (0.55, 0.74)
    </td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">8</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">33</td>
                           <td align="center" styleCode="Botrule Rrule" valign="middle">60</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="italics">
                        <sup>a</sup>Subjects with missing scan interpretation (2% to 6% per group) were excluded from the analyses.
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <sup>b</sup>Shown is the median number of scans interpreted as positive across the 5 readers for each group of subjects listed in the first column.
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Alzheimer’s disease (AD), Mild cognitive impairment (MCI), healthy volunteer (HV). Other dementias include DLB, fronto-temporal lobe dementia, vascular dementia, and dementia associated with PD.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240501"/>
            </section>
         </component>
         <component>
            <section ID="Laef2be25-4f03-40c3-8f8d-3eafc2cb25ec">
               <id root="33d8ccfc-32b3-6154-e063-6294a90a5187"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text/>
               <effectiveTime value="20250314"/>
               <component>
                  <section ID="L8285e4b1-ac19-42e2-bc70-cdb11fe2a81f">
                     <id root="33d8ccfc-32b4-6154-e063-6294a90a5187"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Neuraceq is supplied in a 50 mL glass vial containing up to 50 mL of a clear solution at a strength of 50 MBq/mL to 5,000 MBq/mL (1.4 mCi/mL to 135 mCi/mL) florbetaben F18 at end of synthesis. Each vial contains multiple doses and is enclosed in a shielded container to minimize external radiation exposure.</paragraph>
                        <paragraph>50 mL glass vial: NDC 54828-001-50.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="L2bcbdb61-82d3-452c-a998-11b587b48845">
                     <id root="33d8ccfc-32b5-6154-e063-6294a90a5187"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph>Store Neuraceq at room temperature 25°C (77°F); excursions permitted to 2°C to 42°C (36°F to 108°F).</paragraph>
                        <paragraph>The product does not contain a preservative. Store Neuraceq within the original container or equivalent radiation shielding. Neuraceq must not be diluted.</paragraph>
                        <paragraph>This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.</paragraph>
                     </text>
                     <effectiveTime value="20140324"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L423f526f-9473-4844-8f70-1ae90ecc0b71">
               <id root="33d8ccfc-32b6-6154-e063-6294a90a5187"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>• Instruct patients to inform their physician or healthcare provider if they are pregnant or breastfeeding.</paragraph>
                  <paragraph>• Inform patients who are breastfeeding to use alternate infant nutrition sources (e.g. stored breast milk or infant formula) for 24 hours (&gt;10 half-lives of radioactive decay for the F 18 isotope) after administration of the drug or to avoid use of the drug.</paragraph>
               </text>
               <effectiveTime value="20240501"/>
            </section>
         </component>
         <component>
            <section ID="Lff377c35-29fb-44f0-b207-a086a4180551">
               <id root="33d8ccfc-32b7-6154-e063-6294a90a5187"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Manufactured for Life Molecular Imaging Ltd., 25 Barnes Wallis Road, Fareham, Hampshire, PO15 5TT. United Kingdom. Neuraceq is a registered trademark of Life Molecular Imaging.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
            </section>
         </component>
         <component>
            <section ID="id_link_33d90abd-2ec8-8366-e063-6294a90a515b">
               <id root="33d90abd-2ec7-8366-e063-6294a90a515b"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250428"/>
            </section>
         </component>
         <component>
            <section ID="Le89a3b82-30dd-4001-b756-1b9be50b7728">
               <id root="33d9fbcf-df59-47ed-e063-6294a90a6377"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Neuraceq 50 mL Vial Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_33d9faeb-3389-3e57-e063-6294a90aec5b"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="img_33d9faeb-3389-3e57-e063-6294a90aec5b">
                     <text>Vial Label_2024</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Vial label_2024.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Le89a3b82-30dd-4001-b756-1b9be50b7727">
               <id root="33da0538-ec1a-d5c6-e063-6394a90aebbd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Neuraceq Shield Label for 50 mL Vial</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_33da02a0-def3-4dcc-e063-6294a90a8733"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="img_33da02a0-def3-4dcc-e063-6294a90a8733">
                     <text>shiled label_2024</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="shield label_2024.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>